HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsuboi, Y. Articles by Dickson, D. W. Search for Related Content PubMed PubMed Citation Articles by Tsuboi, Y. Articles by Dickson, D. W. Related Collections Progressive supranuclear palsy Alzheimer's disease

APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy

From the Departments of Neurology (Drs. Tsuboi and Josephs) and Pathology (Neuropathology) (Dr. Dickson and N. Cookson), Mayo Clinic, Jacksonville, FL.

Address correspondence and reprint requests to Dr. Dennis W. Dickson, Department of Neuropathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224; e-mail: dickson.dennis{at}mayo.edu

Objective: To assess demographic and genetic determinants of Alzheimer type pathology in progressive supranuclear palsy (PSP).Methods: From a total of 173 pathologically proven cases of PSP in the Society for PSP Brain Bank, 143 patients (mean age = 74.4 years, ranging from 42 to 98 years) were suitable for genetic and pathologic study. Senile plaques (SPs) and neurofibrillary tangles (NFTs) were counted in five cortical areas, Braak stage was given, and APOE genotype was determined from DNA isolated from frozen brain tissue. The APOE allele frequency in PSP with varying degrees of concomitant Alzheimer type pathology was compared with pure PSP and autopsy controls. The relationship of APOE 4 to quantitative pathologic measures was also assessed.

Results: Most patients with PSP (103 cases) had either minimal or no Alzheimer type pathology (Braak stage III or less), but 14 patients had many SPs (>20 per low power field) and a Braak stage of IV or higher consistent with pathologic criteria for AD, and 26 patients had many diffuse plaques with minimal neurofibrillary degeneration (Braak stage III or less) consistent with pathologic aging. Alzheimer type pathology was more frequent in women and older individuals with PSP, and 19 of the 40 patients with PSP with Alzheimer type pathology carried at least one APOE 4 allele. The 4 allele frequency was significantly higher in PSP with AD or pathologic aging than in pure PSP, and APOE 4 correlated with the average maximal density of both neocortical SPs and NFTs.

Conclusion: APOE 4 is a risk factor for Alzheimer type pathology in PSP. Alzheimer type pathology is an independent process unrelated to PSP in cases with both types of pathologies.

This article has been cited by other articles:

				K. A. Josephs, Y. Tsuboi, N. Cookson, H. Watt, and D. W. Dickson Apolipoprotein E {varepsilon}4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Arch Neurol, October 1, 2004; 61(10): 1579 - 1584. [Abstract] [Full Text] [PDF]

				J. Raber Androgens, ApoE, and Alzheimer's Disease Sci. Aging Knowl. Environ., March 17, 2004; 2004(11): re2 - re2. [Abstract] [Full Text] [PDF]